Zeyan Xu

Zeyan Xu

Auto-generated profile, based on publicly available information

Zeyan Xu

Department of Radiology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Radiology
Verified
Journal Article
Closed access
ZSZhenwei Shi
Zhenwei Shi
XHXiaomei Huang
Xiaomei Huang
ZCZiliang Cheng
Ziliang Cheng
ZXZeyan Xu
Zeyan Xu
HLHuan Lin
Huan Lin
ZLZaiyi Liu
Zaiyi Liu
Background Breast cancer is highly heterogeneous, resulting in different treatment responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative measure of intratumoral heterogeneity (ITH) may be valuable for predicting treatment response. Purpose To develop a quantitative measure of ITH on pretreatment MRI scans and test its performance for predicting pathologic complete response (pCR) after NAC in patients with breast cancer. Materials and Methods Pretreatment MRI scans were retrospectively acquired in patients with breast cancer who received NAC followed by surgery at multiple centers from January 2000 to September 2020. Conventional radiomics (hereafter, C-radiomics) and intratumoral ecological diversity features were extracted from the MRI scans, and output probabilities of imaging-based decision tree models were used to generate a C-radiomics score and ITH index. Multivariable logistic regression analysis was used to identify variables associated with pCR, and significant variables, including clinicopathologic variables, C-radiomics score, and ITH index, were combined into a predictive model for which performance was assessed using the area under the receiver operating characteristic curve (AUC). Results The training data set was comprised of 335 patients (median age, 48 years [IQR, 42-54 years]) from centers A and B, and 590, 280, and 384 patients (median age, 48 years [IQR, 41-55 years]) were included in the three external test data sets. Molecular subtype (odds ratio [OR] range, 4.76-8.39 [95% CI: 1.79, 24.21]; all P < .01), ITH index (OR, 30.05 [95% CI: 8.43, 122.64]; P < .001), and C-radiomics score (OR, 29.90 [95% CI: 12.04, 81.70]; P < .001) were independently associated with the odds of achieving pCR. The combined model showed good performance for predicting pCR to NAC in the training data set (AUC, 0.90) and external test data sets (AUC range, 0.83-0.87). Conclusion A model that combined an index created from pretreatment MRI-based imaging features quantitating ITH, C-radiomics score, and clinicopathologic variables showed good performance for predicting pCR to NAC in patients with breast cancer. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rauch in this issue.

4 July 2025 in Science Advances
Verified
Journal Article
Open access
ZMZongchao Mo
Zongchao Mo
MYMei Yang
Mei Yang
ZZZhihan Zhu
Zhihan Zhu
MWMinghao Wang
Minghao Wang
HWHaoyu Wang
Haoyu Wang
ZLZaiyi Liu
Zaiyi Liu
Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.

27 November 2025 in Expert Systems with Applications
Verified
Journal Article
Closed access
YLYaoqi Liu
Yaoqi Liu
SDSiyao Du
Siyao Du
ZXZeyan Xu
Zeyan Xu
ZZZhen Zhang
Zhen Zhang
ZWZhitao Wei
Zhitao Wei
WLWenbin Liu
Wenbin Liu

13 December 2025 in Digital Signal Processing
Verified
Journal Article
Closed access
XLXiangbin Luo
Xiangbin Luo
ZWZhitao Wei
Zhitao Wei
YLYanting Liang
Yanting Liang
CWChinting Wong
Chinting Wong
ZXZeyan Xu
Zeyan Xu
YWYing Wang
Ying Wang